Russia skips ahead in COVID vaccine race, triggering outcry over unproven 'Sputnik V' shot Kaiser Permanente reports $4.5B in Q2 net income as COVID-19 drives down operating costs Novavax aims for billions of COVID-19 vaccine doses in 2021—more than enough to supply U.S. LabCorp COVID tests free for three months to aide plasma donations Biopharma roundup: Sanofi, Takeda, Lilly execs call for ongoing vax funding; Leerink analyst questions timelines Healthcare roundup: CVS Health launches COVID podcast with health experts Study finds reprocessing N95 masks one time is acceptable alternative if supplies low How Adaptive Biotechnologies and Microsoft are working to 'decode" our immune response to COVID-19 Samsung Biologics plots $2B 'super plant' as COVID-19 sends sales through the roof Charles River Laboratories ‘weathers COVID challenges’ to see healthy growth Featured Story | By Eric Sagonowsky As global players rush to deliver COVID-19 vaccines, Russia shocked the world Tuesday with news that it had approved a locally developed inoculation, provocatively named "Sputnik V." But that approval was based on skimpy data, and experts characterized the move as a risky political stunt. read more |
| |
|---|
|
Top Stories By Paige Minemyer Kaiser Permanente earned $4.5 billion in net income in the second quarter after a "challenging" Q1 as deferred procedures under the pandemic drove down operating costs. read more By Eric Sagonowsky Some of the world’s largest companies are working to deliver safe and effective COVID-19 vaccines, but at the same time, a much smaller biotech has laid out its own big ambitions in the field. Novavax will have billions of doses of COVID-19 vaccine capacity next year and could single-handedly meet U.S. demand, executives said. read more By Ben Adams Leading testing company LabCorp is offering a “no charge” antibody COVID-19 testing program in the hope it will boost blood plasma donations. read more By Eric Sagonowsky, Kyle Blankenship, Angus Liu, Conor Hale Top pharma executives from Sanofi, Takeda, Eli Lilly and Cipla are asking governments to invest upfront in the industry's efforts against COVID-19. An SVB Leerink analyst questions the much-touted timeline of having a vaccine available for general use in less than two years. read more By Healthcare Staff Follow along with the latest COVID-19 news straight from the Fierce Healthcare team. read more By Robert King A new study found that reprocessing and sterilizing N95 masks once didn't lead to them being less effective at filtering out COVID-19 particles. read more By Heather Landi Adaptive Biotechnologies and tech giant Microsoft teamed up in 2018 to “decode” the immune system. The biotech company is using Microsoft's cloud computing and machine learning muscle to map out how the adaptive immune system responds to COVID-19. The aim is to advance vaccine development and new diagnostics. read more By Kyle Blankenship The COVID-19 pandemic has sent shockwaves across the pharmaceutical industry, cutting into sales and disrupting the supply chain. But the crisis hasn't been a bad thing for everyone: South Korea's Samsung Biologics, for instance, is swimming in new orders, and it's planning to build a long-awaited facility to celebrate. read more By Ben Adams Charles River Labs has seen its revenue edge up despite COVID challenges as it looks to buy up cell therapy services provider Cellero. read more |
